Man Group
SYRE icon

Man Group’s Spyre Therapeutics SYRE Stock Holding History

Man Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$482K Buy
+9,546
New +$360K ﹤0.01% 2090
2025
Q3 		– Sell
-10,843
Closed -$162K – 2457
2025
Q2 		$162K Buy
+10,843
New +$160K ﹤0.01% 2098
2022
Q4 		– Sell
-1,379
Closed -$18K – 2210
2022
Q3 		$18K Buy
+1,379
New +$17K ﹤0.01% 1941
2022
Q2 		– Hold
0
– – – 2012
2020
Q1 		– Sell
-1,648
Closed -$315K – 1870
2019
Q4 		$315K Hold
1,648
– – ﹤0.01% 1667
2019
Q3 		$317K Sell
1,648
-2,020
-55% -$393K ﹤0.01% 1654
2019
Q2 		$628K Buy
3,668
+64
+2% +$11.1K ﹤0.01% 1631
2019
Q1 		$725K Sell
3,604
-1,372
-28% -$286K ﹤0.01% 1655
2018
Q4 		$932K Sell
4,976
-7,001
-58% -$1.49M ﹤0.01% 1471
2018
Q3 		$2.87M Sell
11,977
-1,047
-8% -$245K 0.01% 1263
2018
Q2 		$3.44M Buy
+13,024
New +$3.2M 0.01% 1123

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Man Group's SYRE Position: Q1 2026 in Review

Man Group opened a new position in Spyre Therapeutics (SYRE) in Q1 2026: 9,546 shares worth $482K. The stake represents ﹤0.01% of the portfolio and ranks #2090 among its holdings. This is a return to the name: Man Group previously reported a position in SYRE as recently as Q2 2025.

Man Group first reported a position in SYRE in Q2 2018 and has held it in 10 quarters since. The position peaked at $3.44M in Q2 2018. 197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • Man Group held 9,546 shares of Spyre Therapeutics worth $482K as of Q1 2026.
  • Spyre Therapeutics was a new Man Group position in Q1 2026.
  • Spyre Therapeutics made up ﹤0.01% of Man Group's portfolio in Q1 2026, its #2090 holding.
  • Man Group first reported a position in Spyre Therapeutics in Q2 2018 and has held it in 10 quarters since.
  • Man Group's Spyre Therapeutics position peaked at $3.44M in Q2 2018.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.